ArticleAdvanced biomedical research2019
Prostate-Specific Membrane Antigen Expression in Neovasculature of Glioblastoma Multiforme.
Article in Advanced biomedical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Diagnostic significance of neutrophil-to-lymphocyte ratio in non-arteritic anterior ischemic optic neuropathy: a meta-analysis.European journal of medical research · 2024Pooled it
- Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.Molecular imaging · 2022Pooled it
- Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas.Current radiopharmaceuticals · 2020Pooled it
- PSMA-Targeted Theranostics in Glioblastoma Multiforme: Current Evidence and Future Perspectives.International journal of molecular sciences · 2026Review
- Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs.European journal of nuclear medicine and molecular imaging · 2026Review
- Prostate-specific membrane antigen in malignant brain tumors: vascular heterogeneity, imaging promise, and therapeutic challenges.Frontiers in oncology · 2026Review
- Imply on diagnosis and early prognosis of preoperative [Scientific reports · 2025Article
- Modeling Normal Tissue Complication Probability of Radiation-Induced Alopecia Following Intensity-Modulated Radiation Therapy in Glioblastoma Patients.Advanced biomedical research · 2025Article
- Comparison between [International journal of molecular sciences · 2023Article
- Prostate-Specific Membrane Antigen (PSMA) Expression in The Neovasculature of High Grade Gliomas (Histopathological and Immunohistochemical Study).Asian Pacific journal of cancer prevention : APJCP · 2023Article
- PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach.Frontiers in nuclear medicine · 2023Review
- The "Ins and Outs" of Prostate Specific Membrane Antigen (PSMA) as Specific Target in Prostate Cancer Therapy.Advances in experimental medicine and biology · 2023Article
- Advances in PSMA theranostics.Translational oncology · 2022Article
- Incidental prostate-specific membrane antigen-avid glioblastoma detected onRadiology case reports · 2022Article
- A Review on the Current State and Future Perspectives of [Molecules (Basel, Switzerland) · 2022Review
- Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging.Scientific reports · 2022Article
- PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.European journal of nuclear medicine and molecular imaging · 2021Review
- Incidental prostate-specific membrane antigen-avid meningioma detected onRadiology case reports · 2021Article
- PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging.Frontiers in oncology · 2021Article
- A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) is the most malignant brain tumor with a poor prognosis that can be very difficult to cure, and the current treatment options have no optimal outcomes. Hence, it is essential to find new treatment modalities. Histologically, this tumor has high microvascular density that makes it desirable for vascular target agent drugs. Prostate-specific membrane antigen (PSMA) is a novel antigen with unique features that expresses in the vascular endothelium of some malignant tumors. MATERIALS AND
methodsFormalin-fixed paraffin-embedded tissues from sixty patients who underwent GBM tumor resection from 2012 to 2016 were evaluated for the expression of PSMA by immunohistochemistry. Sections were also assessed for the extent and intensity of endothelial staining in tumor microvessels and for clinicopathologic factor correlation.
resultsA considerable PSMA expression level was detected in 66% of the cases, and the intensity was strong and moderate in 63%. There was no significant correlation neither between PSMA expression with tumor site, presence of necrosis, and endothelial proliferation nor with age and sex.
conclusionThe expression of PSMA in GBM, as observed in the current study, may suggest a new role of PSMA-targeted therapy and indicate more investigations focused on complementary treatment strategies that specifically target tumor vasculature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.